Shenqi(SH:600613)2025-04-25 10:00Financial Performance - The company's operating revenue for Q1 2025 was CNY 479,926,834.64, a decrease of 16.47% compared to CNY 574,528,830.84 in the same period last year[6] - Net profit attributable to shareholders was CNY 14,994,496.83, down 37.38% from CNY 23,944,713.73 year-on-year[6] - Total revenue for Q1 2025 was CNY 479,926,834.64, a decrease of 16.5% compared to CNY 574,528,830.84 in Q1 2024[22] - Operating profit for Q1 2025 was CNY 20,881,969.61, a decline of 34.3% compared to CNY 31,746,214.60 in Q1 2024[22] - The net profit for Q1 2025 was 15,717,573.30, a decrease of 37.4% compared to 25,123,136.63 in Q1 2024[23] - The company reported a total comprehensive income of 11,347,415.04 for Q1 2025, down 55.2% from 25,346,836.31 in Q1 2024[23] Cash Flow - The net cash flow from operating activities was negative at CNY -28,774,798.16, a decline of 167.22% compared to CNY 42,806,771.33 in the previous year[6] - The total revenue from operating activities in Q1 2025 was 392,984,135.62, down 23.4% from 512,993,663.80 in Q1 2024[26] - The net cash flow from operating activities for Q1 2025 was -28,774,798.16, compared to 42,806,771.33 in Q1 2024, indicating a significant decline[26] - The company incurred a cash outflow of 421,758,933.78 from operating activities in Q1 2025, compared to 470,186,892.47 in Q1 2024[26] - The net cash flow from financing activities for Q1 2025 was 37,211,883.85, a significant increase from 1,092,398.13 in Q1 2024[27] - The cash inflow from investment activities was -12,618,745.39 for Q1 2025, compared to -2,248,081.46 in Q1 2024, indicating increased cash outflow[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,122,566,299.08, a slight increase of 0.22% from CNY 3,115,812,628.78 at the end of the previous year[6] - Total assets as of March 31, 2025, amounted to CNY 3,122,566,299.08, compared to CNY 3,115,812,628.78 at the end of 2024[19] - Total liabilities decreased to CNY 672,411,521.45 as of March 31, 2025, from CNY 689,005,266.19 at the end of 2024[19] - Shareholders' equity attributable to the parent company increased by 0.45% to CNY 2,373,662,839.07 from CNY 2,363,038,500.50 at the end of the previous year[6] - Shareholders' equity increased to CNY 2,450,154,777.63 as of March 31, 2025, from CNY 2,426,807,362.59 at the end of 2024[19] Research and Development - Research and development expenses decreased by 14.55%, indicating a reduction in R&D investment compared to the previous year[7] - Research and development expenses for Q1 2025 were CNY 7,656,280.53, down from CNY 8,960,100.75 in Q1 2024[22] Other Financial Metrics - Basic and diluted earnings per share decreased by 25.00% to CNY 0.03 from CNY 0.04 in the same period last year[6] - Basic earnings per share for Q1 2025 were 0.03, a decrease from 0.04 in Q1 2024[23] - The company reported a net impairment loss of CNY 3,910,182.42 in Q1 2025, compared to a gain of CNY 90,360.00 in Q1 2024[22] - The company reported a decrease in other comprehensive income, with a net amount of -4,370,158.26 for Q1 2025 compared to 223,699.68 in Q1 2024[23] Future Plans - The company plans to focus on market expansion and new product development in the upcoming quarters[15] Government Subsidies - The company received government subsidies amounting to CNY 281,045.50 during the reporting period[8] Prepayments and Contract Liabilities - The company reported a significant increase in prepayments by 39.57%, primarily due to advance payments for Chinese medicinal materials[7] - Contract liabilities rose by 59.92%, attributed to the receipt of advance payments for goods[7]